Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $64 | $31 | $31 |
| G&A Expenses | $19 | $9 | $6 |
| SG&A Expenses | $19 | $9 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $82 | $40 | $38 |
| Operating Income | -$82 | -$40 | -$38 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $15 | -$12 | -$0 |
| Pre-Tax Income | -$68 | -$52 | -$38 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$68 | -$52 | -$38 |
| % Margin | – | – | – |
| EPS | -1.25 | -1 | -0.73 |
| % Growth | -25% | -37% | – |
| EPS Diluted | -1.25 | -1 | -0.73 |
| Weighted Avg Shares Out | 54 | 52 | 52 |
| Weighted Avg Shares Out Dil | 54 | 52 | 52 |
| Supplemental Information | – | – | – |
| Interest Income | $15 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 |
| EBITDA | -$82 | -$40 | -$38 |
| % Margin | – | – | – |